These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15782619)

  • 1. [Clinical study on development of nontuberculous mycobacterial lung disease].
    Kurashima A
    Kekkaku; 2004 Dec; 79(12):737-41. PubMed ID: 15782619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
    Ogawa K; Sano C
    Kekkaku; 2013 Mar; 88(3):355-71. PubMed ID: 23672176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
    Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
    J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-tuberculous mycobacteriosis. What has been coming out].
    Kajiki A
    Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
    Mizutani S
    Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of non-tuberculous pulmonary mycobacteriosis].
    Sakatani M; Nakajima Y
    Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
    Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
    Kawahara S; Nagare H
    Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease.
    Fujita M; Kajiki A; Tao Y; Miyazaki M; Ouchi H; Harada E; Ikegame S; Matsumoto T; Uchino J; Watanabe K; Nakanishi Y
    J Infect Chemother; 2012 Apr; 18(2):146-51. PubMed ID: 21927844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of pulmonary nontuberculous mycobacteriosis].
    Kurashima A
    Kekkaku; 2002 Dec; 77(12):815-21. PubMed ID: 12607341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
    Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
    BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
    Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE
    Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.
    Adachi Y; Tsuyuguchi K; Kobayashi T; Kurahara Y; Yoshida S; Kagawa T; Hayashi S; Suzuki K
    J Infect Chemother; 2020 Jul; 26(7):676-680. PubMed ID: 32171660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difference in drug susceptibility distribution and clinical characteristics between
    Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
    J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
    Park Y; Lee EH; Jung I; Park G; Kang YA
    Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of clarithromycin monotherapy and long-term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims.
    Iwao T; Kato G; Ito I; Aramaki E; Kuroda T
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):427-432. PubMed ID: 31876044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of new quinolones in the treatment of mycobacteriosis].
    Kekkaku; 2003 Sep; 78(9):601-4. PubMed ID: 14577348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
    Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
    Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
    Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.